Ligand Pharmaceuticals Incorporated LGND 深 沪
交易中 10-08 11:05:08 美东时间
284.11
-9.150
-3.12%
华盛通- 最 高291.52
- 今 开290.41
- 成交量 4.17万股
- 最 低 283.28
- 昨 收 293.26
- 总市值 56.64亿
- 52周最高 326.63
- 市盈率 静 46.33
- 换手率 0.21%
- 52周最低 175.89
- 委 比 -73.44%
- 总股本 1993.56万
- 历史最高 326.63
- 量 比 0.86
- 振 幅 2.81%
- 历史最低 -19.8529
- 每 手 1
- 风险率 44.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%
Pelthos Therapeutics announced new formulary coverage for ZELSUVMI, expanding access to 24 million additional lives through a major PBM and 3 million through a regional health plan. This brings total commercial coverage to 127 million lives and full Medicaid coverage. ZELSUVMI, a topical treatment for molluscum contagiosum, is the first at-home prescription therapy for the condition. The company emphasizes its commitment to improving patient acce...
10-06 12:00
美股大行评级 | Meta获4家机构看好！目标价最高升至950美元；好市多绩后齐遭机构降低目标价
今日重点评级关注：古根海姆：维持Damora Therapeutics"买入"评级，目标价从40美元升至60美元；HC Wainwright & Co.：维持Rezolute"买入"评级，目标价从5美元升至10美元
09-28 12:37
美股大行评级 | Meta获4家机构齐升目标价，最高看至995美元！麦当劳遭6家机构下调，最低看至260美元
今日重点评级关注：Canaccord Genuity：维持Aurora Innovation"买入"评级，目标价从15美元升至17美元；摩根大通：维持皇家加勒比邮轮"超配"评级，目标价从345美元升至394美元
09-25 15:55
美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多
今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元
09-24 16:10
Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round ...
09-22 21:00
Here’s How Much You Would Have Made Owning Ligand Pharmaceuticals Stock In The Last 5 Years
Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 15.5% on an annualized basis producing an average annual return of 27.11%. Currently, Ligand Pharmaceuticals has a market capitalization of $5.67 billion. Buying $100 In LGND: If an investor had bought $100 of ...
09-21 23:00
If You Invested $100 In Ligand Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today
Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 17.28% on an annualized basis producing an average annual return of 28.4%. Currently, Ligand Pharmaceuticals has a market capitalization of $5.72 billion. Buying $100 In LGND: If an investor had bought $100 of ...
09-03 05:00
Ligand to Participate in September Investor Conferences
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announced that its senior management team will participate in three upcoming investor conferences: the Wells Fargo Healthcare Conference 2026 in Boston on September 8, 2026, the Citi 2026 Biopharma Back to School Conference in New York on September 10, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14, 2026. Management will engage in fireside chats...
08-26 11:00
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
Leerink Partners Initiates Coverage On Ligand Pharmaceuticals with Outperform Rating, Announces Price Target of $330
Leerink Partners analyst David Risinger initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform rating and announces Price Target of $330.
08-15 03:52
